As of June 12, 2018 our Privacy Policy has been updated. For individuals in the European Union, CIL uses cookies on this website. Please review the new privacy statement to see how. By continuing to use this website you agree to us using cookies in accordance with our privacy statement. Click here for the new privacy statement..OK

Corporate Overview

Cambridge Isotope Laboratories Appoints Todd Osiek, PhD as Chief Science Officer

July 29, 2020
Cambridge Isotope Laboratories, Inc., the leading manufacturer of stable isotope and stable isotope-labeled compounds worldwide, is pleased to announce the addition of Todd Osiek, PhD, as Chief Science Officer (CSO). Osiek reports directly to the CEO, Cliff Caldwell. As CSO, Osiek is responsible for supporting operations development of best practices in safety and quality, working with sales and marketing on new-product development, and mapping out strategic directions and opportunities.
“Todd was the perfect addition to CIL’s team,” states Caldwell. “He comes to CIL with more than 20 years’ experience in the pharmaceutical industry, supporting various stages of development from discovery to marketed products.”
Osiek recently served as the Director of Analytical Chemistry, Research, at Mallinckrodt Pharmaceuticals, where his team handled all pipeline products, including technical support for method development, transfer, characterization, manufacturing technology transfers, and quality investigations.
“I was very excited when given the opportunity to join the CIL team,” adds Osiek. “I am thrilled to have the opportunity to work with the world leader in the stable isotope business. The future is bright for isotopes with their diverse applications and innovative uses. I look forward to working with CIL’s strong leadership team on the next phase of growth through continual expansion of our stable isotope product offerings, along with driving continuous improvement in our customer service and quality.”
About Cambridge Isotope Laboratories, Inc.
CIL is the world’s largest manufacturer and global supplier of stable isotopes and stable isotopelabeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL is an operating business owned by Otsuka Pharmaceuticals. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. For more information on CIL, visit
For more information on CIL, visit
Back to list
CIL News| Cambridge Isotope Laboratories
metabolic substrates, isotope labeling, SILAC Amino Acids, protein standards, SILAC, Metabolic Labeling, NMR Tubes, Nucleic Acid Synthesis, alpha keto acids, Cell-Free Protein Expression, deuterated compounds, biomolecular nor, stable isotope, Hyperpolarization, nuclear medicine isotopes, Stable Isotopes, protein NMR, Protein Reagents, Deuterium labeled compounds, minimal media, Heavy Isotopes, metabolic research, custom synthesis, mass spectrometry, list of stable isotopes, Quantitative Proteomics, Nuclear Medicine, Metabolomics, food testing, Solid State NMR, proteomics, Membrane Proteins, mass spectrometry isotopes, Nucleic Acid, NMR, Protein Expression, material testing, Peptide Synthesis
CIL and its people have been committed to high quality stable isotope labeled products, superior customer service, innovative new products and a breadth of product lines.